跳至主要内容
临床试验/CTRI/2021/01/030341
CTRI/2021/01/030341尚未招募未知

To study the outcome of COVID 19 positive patients who have received Remdesivir or Tocilizumab or their combination during their treatment in a tertiary care hospital.

Seth G S Medical College and KEM Hospital Mumbai0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Laboratory confirmed COVID 19 adults (Age > 18 years) admitted in KEM Hospital.
  • 2.Patients in ICMR group 2B and onwards.
  • 3.Received any of the following drugs alone or in combination: Remdesivir, Tocilizumab.

排除标准

  • 1. Suspected COVID 19 patients.
  • 2. Positive patients in category 1A to 2A
  • 3. Pregnant/Lactating patients.
  • 4. Mortality within 24 hours of admission.

研究者

发起方
Seth G S Medical College and KEM Hospital Mumbai

相似试验